

EQA round: T05/24 - Immunophenotypisation (study)

Deadline: 22.4.2024

Setup: groups - M (gating strategy); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(637) B lymphocytes (CD5+CD19+)	[% of B]				5							5	4	80
Sample A												5	4	80
(0) Not specified		10,1	5	49	5	0	CVP	15,8	7,4	100%	0	31,6	5	
Sample B												5	4	80
(0) Not specified		8,1	4,2	51	5	0	CVP	13,1	6,6	100%	0	26,2	5	
(638) Isotype switched memory B lymphocytes	[% of B]				5							5	4	80
Sample A												5	4	80
Other					5	0						5		
							4x 1, 1x 2							
Sample B												5	4	80
Other					5	0						5		
							4x 1, 1x 2							
(639) Naive B lymphocytes	[% of B]				7							7	5	71
Sample A		57,7	9,2	16	7		CVP	61,1	3,7	20%	48,8	73,4	7	6
(2) CD19+CD27-IgD+		58,8	3,1	5,3	5	0							5	
Other					2	0							2	
							1x 1, 1x 3							
Sample B		66,4	18	27	7		CVP	75,4	2,3	10%	67,8	83	7	5
(2) CD19+CD27-IgD+		75	5,1	6,8	5	0							5	
Other					2	0							2	
							1x 1, 1x 3							
(640) Activated T lymphocytes (HLA-DR+)	[% of T]				16							16	14	88
Sample A												16	14	88
(0) Not specified		3,84	2,7	71	16	0	CVP	3,99	1	100%	0	7,98	16	
Sample B												16	16	100
(0) Not specified		7,73	4,2	55	16	0	CVP	7,86	1,5	100%	0	15,8	16	
(641) gamma-delta T lymphocytes (CD3+TcRγδ+)	[% of T]				5							5	5	100
Sample A												5	5	100
(0) Not specified		4,65	0,22	4,8	5	0	CVP	4,82	0,45	40%	2,89	6,75	5	
Sample B												5	5	100
(0) Not specified		6,05	1,1	18	5	0	CVP	6,45	0,75	40%	3,87	9,03	5	
(642) T regulatory lymphocytes	[% of Th]				11							11	10	91
Sample A		4,24	1,5	34	11		CVP	3,93	0,73	70%	1,17	6,69	11	10
(1) CD3+CD4+CD25+CD127low		4,43	1,4	30	10	0							10	
Other					1	0							1	
							1x 99							
Sample B		5,81	1,6	28	11		CVP	5,75	0,72	70%	1,72	9,78	11	11
(1) CD3+CD4+CD25+CD127low		5,76	1,7	30	10	0							10	
Other					1	0							1	
							1x 99							
(643) Naive Th lymphocytes	[% of Th]				7							7	7	100
Sample A												7	7	100
(1) CD3+CD4+CD45RA+		34	11	34	7	0	CVP	35	5,8	55%	15,7	54,3	7	
Sample B												7	7	100
(1) CD3+CD4+CD45RA+		35,7	16	46	7	0	CVP	36,9	5,5	55%	16,6	57,2	7	
(630) WBC	[·10 ⁹ /L]				12							12	9	75
Sample A												12	10	83
(0) Not specified		2,7	0,23	8,6	12	0	CVP	2,87	0,093	15%	2,43	3,31	12	
Sample B												12	11	92
(0) Not specified		3,06	0,15	5,1	12	0	CVP	3,01	0,057	10%	2,7	3,32	12	
(631) Lymphocytes	[·10 ⁹ /L]				12							12	11	92
Sample A												12	11	92
(0) Not specified		1,22	0,17	14	12	1	CVP	1,3	0,087	30%	0,91	1,69	12	
Sample B												12	11	92
(0) Not specified		0,818	0,14	17	12	1	CVP	0,818	0,062	30%	0,572	1,07	12	
(644) B lymphocytes (CD5+CD19+)	[·10 ⁹ /L]				5							5	3	60
(abs. count)														
Sample A												5	4	80
(0) Not specified		0,066	0,024	36	5	0	CVP	0,044	0,021	100%	0	0,088	5	
Sample B												5	3	60
(0) Not specified		0,052	0,071	140	5	0	CVP	0,019	0,01	100%	0	0,038	5	

EQA round: T05/24 - Immunophenotypisation (study)

Deadline: 22.4.2024

Setup: groups - M (gating strategy); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(645) Isotype switched memory B lymphocytes (abs. count)	[·10 ⁹ /L]				4							4	4	100
Sample A												4	4	100
Other					4	0						4		
							3x 1, 1x 2							
Sample B												4	4	100
Other					4	0						4		
							3x 1, 1x 2							
(646) Naive B lymphocytes (abs. počet)	[·10 ⁹ /L]				6							6	5	83
Sample A												6	5	83
Other					6	0						6		
							1x 1, 4x 2, 1x 3							
Sample B												6	5	83
Other					6	0						6		
							1x 1, 4x 2, 1x 3							
(647) Activated T lymphocytes (HLA-DR+) (abs.c)	[·10 ⁹ /L]				13							13	9	69
Sample A												13	10	77
(0) Not specified		0,052	0,053	100	13	0	CVP	0,04	0,013	100%	0	0,08	13	
Sample B												13	11	85
(0) Not specified		0,053	0,035	67	13	0	CVP	0,049	0,011	100%	0	0,098	13	
(648) gamma-delta T lymphocytes(CD3+TcRγδ+) (abs. count)	[·10 ⁹ /L]				4							4	4	100
Sample A												4	4	100
Other					4	0						4		
							4x 0							
Sample B												4	4	100
Other					4	0						4		
							4x 0							
(649) T regulatory lymphocytes (abs. count)	[·10 ⁹ /L]				9							9	7	78
Sample A		0,025	0,017	69	9		CVP	0,029	0,01	100%	0	0,058	9	7
(1) CD3+CD4+CD25+CD127low		0,042	0,042	100	8	0						8		
Other					1	0						1		
							1x 99							
Sample B		0,025	0,011	45	9		CVP	0,03	0,011	100%	0	0,06	9	8
(1) CD3+CD4+CD25+CD127low		0,037	0,035	95	8	0						8		
Other					1	0						1		
							1x 99							
(650) Naive Th lymphocytes (abs. count)	[·10 ⁹ /L]				6							6	5	83
Sample A												6	5	83
(1) CD3+CD4+CD45RA+		0,203	0,07	35	6	0	CVP	0,206	0,067	100%	0	0,412	6	
Sample B												6	5	83
(1) CD3+CD4+CD45RA+		0,14	0,076	54	6	0	CVP	0,137	0,053	100%	0	0,274	6	